DRUG UTILIZATION PATTERNS AND COSTS FOR ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) IN A MANAGED CARE CANCER POPULATION RECEIVING CHEMOTHERAPY

Author(s)

R Scott Mckenzie, MD, Regional Director, Outcomes Research1, Antoine Gosselin, MA, Senior Economist2, Marie-Helene Lafeuille, MA, Economist3, Brahim Bookhart, MBA, MPH, Associate Director Outcomes Research1, Patrick Lefebvre, MA, Vice President3, Francis Vekeman, MA, Economist2, Catherine Tak Piech, MBA, Vice President, Outcomes Research and Biometrics11Ortho Biotech Clinical Affairs, LLC, Bridgewater, NJ, USA; 2 Groupe d'Analyse, Ltée, Montréal, QC, Canada; 3 Groupe d'analyse, Ltee, Montreal, QC, Canada

Objective: To assess current utilization patterns and costs for epoetin alfa (EPO) and darbepoetin alfa (DARB), two ESAs, in managed care cancer patients receiving chemotherapy. Methods: Medical claims from the Ingenix Impact National Managed Care Database between January 2006 and June 2007 were analyzed. Patients included were =18 years old, had =1 claim for cancer within 90 days prior to treatment initiation, were newly initiated on EPO or DARB with =2 doses of either drug, and received chemotherapy during ESA treatment. Mean cumulative ESA dose was used to calculate ESA cost (based on October 2007 wholesale acquisition cost [WAC]) and dose ratio. Results: A total of 2322 EPO and 4353 DARB formed the study population. EPO patients were older (57.7 vs. 55.7 years; p<0.0001) and a lower proportion were women (65% vs. 69%; p=0.0002), compared to DARB patients. Mean ESA treatment duration was slightly longer in the EPO group (59 vs. 55 days; p=0.0001). The mean cumulative dose (SD) was 312,723 (255,432) Units for EPO and 1174 (833) mcg for DARB, resulting in a dose ratio of 266:1 (Units EPO:mcg DARB). Based on these doses, WAC-based ESA cost was 28% less for EPO than for DARB (EPO $3915; DARB $5434; p<0.0001). A sensitivity analysis using January 2008 average sales price+6% also indicated lower cost for EPO (EPO $2803; DARB $3396; p<.0001). This finding was also maintained after adjusting for age, gender, treatment duration, payer type, type of malignancies, cancer treatments, and severity indicators, (adjusted cost difference:$1788, p<0.0001). Conclusion: This observational study of 6675 cancer patients reported a dose ratio of 266:1 which resulted in a 28% lower drug cost in the EPO group compared to the DARB group. These findings provide greater understanding of current real-world ESA utilization in the managed care setting.

Conference/Value in Health Info

2008-05, ISPOR 2008, Toronto, Ontario, Canada

Value in Health, Vol. 11, No. 3 (May/June 2008)

Code

PCN89

Topic

Health Service Delivery & Process of Care

Topic Subcategory

Prescribing Behavior

Disease

Oncology

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×